<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01933568</url>
  </required_header>
  <id_info>
    <org_study_id>N12HYB</org_study_id>
    <nct_id>NCT01933568</nct_id>
  </id_info>
  <brief_title>Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.</brief_title>
  <acronym>N12HYB</acronym>
  <official_title>Combined Stereotactic Radiotherapy and Conventional Fractionation in Stage II and III Non Small Cell Lung Cancer (NSCLC) With Peripheral Tumors Smaller Than 5 cm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I trial is being conducted in patients with inoperable locally advanced NSCLC to&#xD;
      treat with a combination of Conventional Fractionated Radiotherapy (CFRT) on the mediastinal&#xD;
      lymph nodes and Stereotactic Ablative Radiotherapy (SABR)on the primary tumor with concurrent&#xD;
      chemotherapy. It is hypothesized that this will lead to an increase of local control and&#xD;
      overall survival&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In locally advanced NSCLC local control has been poor, but with SABR remarkable high local&#xD;
      control rates with low toxicity have been reported. Currently stage III and inoperable II&#xD;
      NSCLC patients have been treated with IMRT and concurrent chemotherapy at out institute. In&#xD;
      this study we will explore the combination of SABR and CFRT with concurrent chemotherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2013</start_date>
  <completion_date type="Actual">November 11, 2018</completion_date>
  <primary_completion_date type="Actual">November 11, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean-lung dose that is associated with a 15% probability of dose limiting toxicity, defined according to the CTCAE v4; radiation pneumonitis ≥ grade 3 and radiation induced dyspnea ≥ grade 3.</measure>
    <time_frame>2 yrs</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Inoperable Locally Advanced Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combined CFRT and SABR with concurrent cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SABR</intervention_name>
    <description>combined CFRT and SABR with concurrent cisplatin</description>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>combined CFRT and SABR with concurrent cisplatin</description>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytological or histological proven NSCLC stage III or inoperable stage II,&#xD;
             cT1-2a-3N1-3M0 with peripheral tumors &lt; 5 cm (chest wall infiltration is no exclusion&#xD;
             criteria if the tumor diameter is &lt; 5 cm).&#xD;
&#xD;
          -  Weight loss &lt; 10% in the last three months&#xD;
&#xD;
          -  WHO-performance status ≤ 2&#xD;
&#xD;
          -  Patients that receive concurrent chemoradiotherapy, with the exception of adriamycin&#xD;
             and gemcitabine&#xD;
&#xD;
          -  FEV1 and DLCO &gt; 40 % of the age-adjusted normal value&#xD;
&#xD;
          -  Minimum required laboratory data bone marrow reserve and hepatic- and renal function&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Before patient registration, written informed consent must be given according to GCP&#xD;
             and national regulations&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients with central tumors &lt; 2 cm of the proximal bronchial tree (Figure 2) or&#xD;
             tumors immediately adjacent to mediastinal or pericardial pleura.&#xD;
&#xD;
          -  Patients that receive sequential chemoradiotherapy or radiotherapy only.&#xD;
&#xD;
          -  Patients with grade 3 dyspnea at baseline (according to CTCAE version 4.03)&#xD;
&#xD;
          -  Patients with Pancoast tumors&#xD;
&#xD;
          -  Prior radiotherapy treatment to the thorax&#xD;
&#xD;
          -  Any contraindications to the administration of thoracic radiotherapy&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Peulen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 28, 2013</study_first_submitted>
  <study_first_submitted_qc>August 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2013</study_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

